• Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.

      Woestenberg, Petra J; Bogaards, Johannes A; King, Audrey J; Leussink, Suzan; van der Sande, Marianne Ab; Hoebe, Christian Jpa; van Benthem, Birgit Hb (2018-11-13)
      Data on the impact of human papillomavirus (HPV) vaccination on the population HPV prevalence are largely obtained from women. We assessed the impact of the girls-only HPV16/18 vaccination program in the Netherlands that started in 2009, on trends in HPV prevalence among women and heterosexual men, using data from the PASSYON study. In this cross-sectional study, the HPV prevalence among 16- to 24-year-old visitors to sexually transmitted infection clinics was assessed in 2009, 2011, 2013, and 2015. We compared the genital postvaccination HPV prevalence with the prevaccination prevalence (2009) using Poisson GEE models. In total, we included 4,996 women and 1,901 heterosexual men. The percentage of women who reported to be vaccinated increased from 2.3% in 2009 to 37% in 2015. Among all women, the HPV16/18 prevalence decreased from 23% prevaccination to 15% in 2015 (adjusted prevalence ratio [aPR] 0.62, p
    • Bivalent human papillomavirus (HPV) vaccine effectiveness correlates with phylogenetic distance from HPV vaccine types 16 and 18.

      Bogaards, Johannes A; van der Weele, Pascal; Woestenberg, Petra J; van Benthem, Birgit H B; King, Audrey J (2019-06-04)
    • Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands.

      Woestenberg, Petra J; King, Audrey J; Van Benthem, Birgit H B; Leussink, Suzan; Van der Sande, Marianne A B; Hoebe, Christian J P A; Bogaards, Johannes A (2019-04-23)
    • Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.

      Woestenberg, Petra J; King, Audrey J; van Benthem, Birgit H B; Donken, Robine; Leussink, Suzan; van der Klis, Fiona R M; de Melker, Hester E; van der Sande, Marianne A B; Hoebe, Christian J P A; Bogaards, Johannes A (2018-01-04)
      Observational postmarketing studies are important to assess vaccine effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine against HPV positivity of vaccine and nonvaccine types in a high-risk population.
    • Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies.

      Wei, Feixue; Gaisa, Michael M; D'Souza, Gypsyamber; Xia, Ningshao; Giuliano, Anna R; Hawes, Stephen E; Gao, Lei; Cheng, Shu-Hsing; Donà, Maria Gabriella; Goldstone, Stephen E; et al. (2021-07-30)
      The systematic review identified 93 eligible studies, of which 64 contributed data on 29 900 men to the pooled analysis. Among HIV-negative MSW anal HPV16 prevalence was 1·8% (91 of 5190) and HR-HPV prevalence was 6·9% (345 of 5003); among HIV-positive MSW the prevalences were 8·7% (59 of 682) and 26·9% (179 of 666); among HIV-negative MSM they were 13·7% (1455 of 10 617) and 41·2% (3798 of 9215), and among HIV-positive MSM 28·5% (3819 of 13 411) and 74·3% (8765 of 11 803). In HIV-positive MSM, HPV16 prevalence was 5·6% (two of 36) among those age 15-18 years and 28·8% (141 of 490) among those age 23-24 years (ptrend=0·0091); prevalence was 31·7% (1057 of 3337) among those age 25-34 years and 22·8% (451 of 1979) among those age 55 and older (ptrend<0·0001). HPV16 prevalence in HIV-negative MSM was 6·7% (15 of 223) among those age 15-18 and 13·9% (166 of 1192) among those age 23-24 years (ptrend=0·0076); the prevalence plateaued thereafter (ptrend=0·72). Similar age-specific patterns were observed for HR-HPV. No significant differences for HPV16 or HR-HPV were found by age for either HIV-positive or HIV-negative MSW. HSIL+ detection ranged from 7·5% (12 of 160) to 54·5% (61 of 112) in HIV-positive MSM; after adjustment for heterogeneity, HIV was a significant predictor of HSIL+ (aPR 1·54, 95% CI 1·36-1·73), HPV16-positive HSIL+ (1·66, 1·36-2·03), and HSIL+ in HPV16-positive MSM (1·19, 1·04-1·37). Among HPV16-positive MSM, HSIL+ prevalence increased with age.
    • Evidence for missing HPV-45 and -59 positives with the SPF-DEIA-LiPA (version 1) platform compared to the type-specific qPCR assays and the impact on vaccine effectiveness estimates.

      van Eer, Kahren; Leussink, Suzan; Severs, Tim T; van Marm-Wattimena, Naomi; Woestenberg, Petra J; Bogaards, Johannes A; King, Audrey J (2020-09-09)
      Human papillomavirus (HPV) epidemiological and vaccine studies require highly sensitive HPV detection systems. The widely used broad-spectrum SPF10-DEIA-LiPA25 (SPF10 method) has reduced sensitivity towards HPV-45 and -59. Therefore, anogenital samples from the PASSYON study were retrospectively analyzed with type-specific (TS) HPV-45 and -59 qPCR assays. The SPF10 method missed 51.1% of HPV-45 and 76.1% of HPV-59 infections, detected by the TS qPCR assays. Viral copy number (VCn) of SPF10 missed HPV-45 and -59 was significantly lower than SPF10 detected HPV-45 and -59 (p<0.0001 for both HPV types). Sanger sequencing showed no phylogenetic distinction between SPF10 missed and detected HPV-59 variants, but variants bearing the A6562G SNP in the SPF10 target region were more likely to be missed (p=0.0392). HPV co-occurrence slightly influenced the detection probability of HPV-45 and -59 with the SPF10 method. Moreover, HPV-59 detection with the SPF10 method was hampered more in non-vaccinated women than vaccinated women, likely due a stronger masking effect by increased HPV co-occurrence in the former group. Consequentially, the SPF10 method led to a strong negative vaccine effectiveness (VE) of -84.6% against HPV-59 while the VE based on TS qPCR was 3.1%. For HPV45, the relative increase in detection in non-vaccinated women compared vaccinated women was more similar, resulting in comparable VE estimates. In conclusion, this study shows that HPV-45 and -59 detection with SPF10 method is dependent on factors including VCn, HPV co-occurrence, and vaccination, thereby showing that knowledge of the limitations of the HPV detection method used is of great importance.
    • HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination.

      Woestenberg, Petra J; van Benthem, Birgit H B; Bogaards, Johannes A; King, Audrey J; van der Klis, Fiona R M; Pasmans, Hella; Leussink, Suzan; van der Sande, Marianne A B; Hoebe, Christian J P A (2020-03-19)
    • Partial protective effect of bivalent HPV16/18 vaccination against anogenital warts in a large cohort of Dutch primary care patients.

      Woestenberg, Petra J; Guevara Morel, Alejandra E; Bogaards, Johannes A; Hooiveld, Mariëtte; van 't Klooster, Tessa M Schurink; Hoebe, Christian J P A; van der Sande, Marianne A B; van Benthem, Birgit H B (2020-05-17)
    • Population impact of girls-only HPV16/18 vaccination in the Netherlands: cross-protective and second-order herd effects.

      Hoes, Joske; Woestenberg, Petra J; Bogaards, Johannes A; King, Audrey J; de Melker, Hester E; Berkhof, Johannes; Hoebe, Christian J P A; van der Sande, Marianne A B; van Benthem, Birgit H B (2020-11-28)